Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00852332|
Recruitment Status : Recruiting
First Posted : February 27, 2009
Last Update Posted : November 17, 2017
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Dietary supplements, such as phytochemicals, may stop or delay the development of breast cancer. It is not yet known whether giving docetaxel together with a phytochemical is more effective than giving docetaxel alone in treating patients with breast cancer.
PURPOSE: This randomized phase II trial is studying how well giving docetaxel together with a phytochemical works compared with giving docetaxel alone as first- or second-line therapy in treating patients with breast cancer.
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer||Dietary Supplement: Curcumin Drug: Taxotere||Phase 2|
- To compare the response rate in HER2-negative patients with locally advanced or metastatic breast cancer or locoregional breast cancer recurrence treated with docetaxel and a dietary phytochemical vs docetaxel alone.
- To compare the overall clinical benefit rate (i.e., objective response plus stable disease) in patients treated with these regimens.
- To compare time to progression in patients treated with these regimens.
- To compare overall survival of patients treated with these regimens.
- To assess biomarkers of response in blood samples from patients treated with these regimens.
OUTLINE: This is a multicenter study. Patients are stratified according to recruitment center and line of chemotherapy (first vs second line of docetaxel). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive docetaxel IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive docetaxel as in arm I. Patients also receive an oral dietary phytochemical twice on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
After completion of study therapy, patients are followed periodically.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-label, Randomised, Phase II Study of Docetaxel in Combination With a Dietary Phytonutrient in First or Second Line Treatment for Patients With HER2 Negative Locally Advanced or Metastatic Breast Cancer, or Loco-regional Recurrence Not Amenable to Treatment by Surgery or Radiotherapy.|
|Study Start Date :||August 2009|
|Actual Primary Completion Date :||October 2017|
With curcumin capsules
|Dietary Supplement: Curcumin Drug: Taxotere|
Active Comparator: Drug taxotere only
- Response rate as assessed by RECIST criteria [ Time Frame: From the date of randomization until the end of the treatment, assessed up to 21 weeks ]
- Overall clinical benefit rate as assessed by RECIST criteria [ Time Frame: From the date of randomization until the end of the treatment, assessed up to 21 weeks ]
- Time to progression as assessed by RECIST criteria [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, assessed up to 21 weeks ]
- Overall survival as assessed by RECIST criteria [ Time Frame: From the date of randomization until the date of death from any cause ]Evaluate overall survival (between inclusion and death whatever the cause)
- Safety as assessed by NCI CTCAE v3.0 [ Time Frame: From the date of randomization until the end of the treatment, assessed up to 21 weeks ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00852332
|Centre Jean Perrin||Recruiting|
|Clermont-Ferrand, France, 63011|
|Contact: Philippe Chollet, MD, PhD 33-4-7327-8198 firstname.lastname@example.org|
|Principal Investigator:||Philippe Chollet, MD, PhD||Centre Jean Perrin|